Next-Generation Sequencing and the Looming Era of the $1,000 Genome

From academia to industry and from popular press to Wall Street, the amount of attention and coverage devoted to new sequencing technologies is unprecedented. But in a world of real research, clinical and diagnostic needs—and real, pressing deadlines—how can your organization actually take advantage of sequencing today? Biocom has organized a panel discussion to explore this question with representatives from Life Technologies, Pfizer, Illumina, and Gigagen. Xconomy also has organized an Oct. 24 forum at UC San Francisco on computing in the age of the $1,000 genome. Registration at the door and networking for the Biocom event begins at 7:30 a.m. Biocom has more information and online registration for its event here.